Investment Thesis
Organogenesis is unprofitable with operating losses of $68.9M against $37.2M revenue, generating massive negative returns (ROE: -21.7%, ROA: -10.2%) despite moderate revenue growth of 17% YoY. While the company maintains adequate liquidity (3.53x current ratio) and generates positive free cash flow of $18.0M, the operational burn rate and inability to approach profitability at current scale present significant fundamental concerns without clear evidence of a path to sustainable operations.
Strengths
- Revenue growing at 17% year-over-year demonstrating market demand
- Positive free cash flow of $18.0M despite net losses, indicating strong working capital management
- Strong liquidity position with 3.53x current ratio and $91.4M cash reserve
Risks
- Deeply unprofitable with $53.2M net loss and $68.9M operating loss against only $37.2M revenue - unsustainable burn rate
- Negative returns on equity (-21.7%) and assets (-10.2%) indicate value destruction
- Anomalous gross margin of 169.1% (exceeding 100%) suggests unusual accounting adjustments or data quality issues requiring clarification
- Negative interest coverage ratio (-60.8x) indicates inability to service debt from operations
- No evident path to profitability or operating margin improvement at current operational scale
Key Metrics to Watch
- Operating margin expansion and timeline to profitability
- Revenue growth acceleration needed to justify operating expense base
- Sustainability of positive operating cash flow as company scales
- Nature and magnitude of non-cash charges driving wedge between net income and cash flow
Financial Metrics
Revenue
37.2M
Net Income
-53.2M
EPS (Diluted)
$-0.44
Free Cash Flow
18.0M
Total Assets
520.0M
Cash
91.4M
Profitability Ratios
Gross Margin
169.1%
Operating Margin
-185.1%
Net Margin
-142.8%
ROE
-21.7%
ROA
-10.2%
FCF Margin
48.3%
Balance Sheet & Liquidity
Current Ratio
3.53x
Quick Ratio
3.16x
Debt/Equity
0.25x
Debt/Assets
26.7%
Interest Coverage
-60.75x
Long-term Debt
62.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:05:55.122718 |
Data as of: 2026-03-31 |
Powered by Claude AI